Nonmalignant cutaneous findings associated with vemurafenib

Cutis. 2018 Jan;101(1):E2-E4.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects
  • Biopsy / methods
  • Diagnosis, Differential
  • Drug-Related Side Effects and Adverse Reactions* / diagnosis
  • Drug-Related Side Effects and Adverse Reactions* / etiology
  • Drug-Related Side Effects and Adverse Reactions* / pathology
  • Drug-Related Side Effects and Adverse Reactions* / therapy
  • Exanthema* / chemically induced
  • Exanthema* / diagnosis
  • Exanthema* / pathology
  • Exanthema* / therapy
  • Female
  • Humans
  • Indoles* / administration & dosage
  • Indoles* / adverse effects
  • Melanoma / drug therapy*
  • Melanoma / genetics
  • Melanoma / pathology
  • Middle Aged
  • Mutation
  • Neoplasm Staging
  • Proto-Oncogene Proteins B-raf / genetics
  • Skin / pathology*
  • Skin Neoplasms / diagnosis*
  • Sulfonamides* / administration & dosage
  • Sulfonamides* / adverse effects
  • Treatment Outcome
  • Vemurafenib
  • Withholding Treatment

Substances

  • Antineoplastic Agents
  • Indoles
  • Sulfonamides
  • Vemurafenib
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf